Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487352 | 0.85 | GSK3B (0.42) | CDK4GSK3BKDRDRD2DRD3 | |
| SCHEMBL5875496 | 0.82 | CSNK1D (0.45) | CDK4GSK3BMAPK8MAPK9MAPK10 | |
| SCHEMBL6488212 | 0.73 | GSK3B (0.50) | CDK4GSK3BKDR | |
| SCHEMBL5388522 | 0.71 | MAPK14 (0.56) | CDK4GSK3BMAPK8MAPK9 | |
| SCHEMBL6487572 | 0.70 | EIF2AK2 (0.50) | CDK4MAPK8MAPK9MAPK10 | |
| SCHEMBL6498415 | 0.68 | MAPK8 (0.46) | CDK4GSK3BKDRMAPK8MAPK9 | |
| SCHEMBL5875531 | 0.68 | MAPK14 (0.54) | CDK4GSK3BMAPK8MAPK9MAPK10 | |
| SCHEMBL5385928 | 0.65 | MAPK14 (0.54) | CDK4GSK3BMAPK8MAPK9MAPK10 | |
| SCHEMBL5890537 | 0.65 | CSNK1D (0.44) | CDK4GSK3BKDRCCNB2CDK1 | |
| SCHEMBL5398657 | 0.65 | MAPK9 (0.56) | CDK4GSK3BKDRMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | CDK4 439/4885GSK3B 3047/4885KDR 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.